NCT03256981 (HALT) is a Phase 2, PHASE3 clinical trial of SBRT in NSCLC, sponsored by Institute of Cancer Research, United Kingdom.

Who is sponsoring NCT03256981?

NCT03256981 is sponsored by Institute of Cancer Research, United Kingdom.

What drugs are being tested in NCT03256981?

Interventions in NCT03256981: SBRT, TKI.

Is NCT03256981 still recruiting?

NCT03256981 is currently status unknown. Last updated 26 December 2023.

Last reviewed 2023-12-26 · How we verify

NCT03256981: HALT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactic Body Radiotherapy for the Treatment of OPD

Status unknown Phase 2, PHASE3 Last updated 26 December 2023

What this trial tests

Phase 2, PHASE3 trial testing SBRT in NSCLC in 113 participants. Status unknown.

Timeline

27 November 2017

Primary endpoint
17 July 2023

30 June 2025

Quick facts

Lead sponsor	Institute of Cancer Research, United Kingdom
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	113
Start date	27 November 2017
Primary completion	17 July 2023
Estimated completion	30 June 2025
Sites	29 locations across France, Italy, United Kingdom, Switzerland, Spain

Drugs / interventions tested

SBRT — full drug profile →
TKI — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →

Sponsor

Institute of Cancer Research, United Kingdom

Who can join

16 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HALT is a phase II, randomised multi-centre study with integrated seamless continuation to phase III trial following acceptable safety and feasibility assessment. HALT aims to recruit 110 patients with mutation positive advanced NSCLC with oligoprogressive disease (OPD) following initial response to a Tyrosine Kinase Inhibitor (TKI).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Patel PH, Palma D, McDonald F, Tree AC. · · 2019 · cited 79× · PMID 31182289 · DOI 10.1016/j.clon.2019.05.015
Metastasis-directed therapy for oligometastasis and beyond.
Beckham TH, Yang TJ, Gomez D, Tsai CJ. · · 2021 · cited 36× · PMID 33204024 · DOI 10.1038/s41416-020-01128-5
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.
Desai A, Lovly CM. · · 2023 · cited 32× · PMID 37057106 · DOI 10.21037/tlcr-22-708
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
Hosoya K, Fujimoto D, Morimoto T, Kumagai T, et al · · 2021 · cited 32× · PMID 33794809 · DOI 10.1186/s12885-021-08048-4
The current state of oligometastatic and oligoprogressive non-small cell lung cancer.
Tumati V, Iyengar P. · · 2018 · cited 29× · PMID 30206497 · DOI 10.21037/jtd.2018.07.19
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer.
Delahaye C, Figarol S, Pradines A, Favre G, et al · · 2022 · cited 25× · PMID 35681591 · DOI 10.3390/cancers14112613
Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
Kroeze SGC, Schaule J, Fritz C, Kaul D, et al · · 2021 · cited 24× · PMID 33407611 · DOI 10.1186/s13014-020-01730-0
Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives.
Kinj R, Muggeo E, Schiappacasse L, Bourhis J, et al · · 2022 · cited 22× · PMID 35267460 · DOI 10.3390/cancers14051152

Verify or expand the search:

Other trials of SBRT

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07451795 — SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC · Phase 2 · recruiting
NCT07410234 — Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity · Phase 2 · not yet recruiting

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Institute of Cancer Research, United Kingdom trials

Trials by the same sponsor.

NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03256981 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
Last refreshed: 26 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03256981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing